Lansoprazole for maintenance therapy of peptic ulcer: Weekend full-dose or everyday half-dose?

Hoshino, Eiji; Oose, Takayuki; Oobayashi, Taminori; Miyashita, Hiroko; Sano, Junjiro; Kimura, M.; Yahagi, Naohisa; Oka, Masanao; Miki, K; Umeda, Noritsugu

doi:10.1016/0016-5085(95)23132-3

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study patients with a history of duodenal ulcer disease received lansoprazole 15 mg once daily for up to 1 year, and a remission rate of 84% was seen at 12 months 11 . In another study patients with a recently healed duodenal ulcer received either lansoprazole 15 mg daily or lansoprazole 30 mg at weekends, both for 6 months; the results showed complete remission 12 …”

Section: Discussionmentioning

confidence: 98%

Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse

Bardhan

Crowe

Thompson

et al. 1999

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Aim : To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly. Methods : A double‐blind, parallel group, randomized multicentre study conducted in 33 centres in the UK, Eire, Sweden and Australia. Two hundred and nineteen patients with a duodenal ulcer were randomized to receive lansoprazole 30 mg and 217 to receive ranitidine 300 mg for 8 weeks. Patients were then re‐randomized to receive lansoprazole 30 mg (122 patients), lansoprazole 15 mg (121 patients) or ranitidine 150 mg (116 patients) for 12 months. All patients had an endoscopically‐proven duodenal ulcer at baseline and were considered suitable for long‐term maintenance therapy to prevent relapse. Results : Significantly more patients were healed on lansoprazole (98%) compared to ranitidine (89%) (P < 0.001, Fisher's exact test). Lansoprazole provided more rapid symptom relief than ranitidine. Lansoprazole 30 mg and lansoprazole 15 mg increased the probability of not relapsing in comparison to ranitidine (P = 0.001 and 0.06, respectively, life‐table analysis). Relapse rates over the 12 months were lower in the lansoprazole treatment groups (lansoprazole 30 mg, 5%; lansoprazole 15 mg, 12%; and ranitidine, 21%; lansoprazole 30 mg vs. ranitidine 150 mg, P = 0.002). Symptoms were well controlled in both groups during the maintenance phase. All treatments were well tolerated with no major differences seen in adverse event profiles between treatment groups. Conclusions : Both doses of lansoprazole (30 mg and 15 mg) were superior to ranitidine 150 mg in the prevention of duodenal ulcer relapse. Lansoprazole was superior to ranitidine in terms of symptom control and duodenal ulcer healing. Both treatments were well tolerated.

show abstract

Section: Discussionmentioning

confidence: 98%

Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse

Bardhan

Crowe

Thompson

et al. 1999

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Lansoprazole a class of proton pump inhibitor (PPI) drug, which is widely used in conditions where gastric secretion inhibition may be beneficial like in the treatment of peptic ulcer disease [15,16]. It has been reported that PPIs presents both antioxidant as well as anti-inflammatory action beyond its role of acid suppression [17].…”

Section: Introductionmentioning

confidence: 99%

Lansoprazole a Proton Pump Inhibitor Prevents IBD by Reduction of Oxidative Stress and NO Levels in the Rat

Gandhi¹,

Sharma²,

Vyas³

et al. 2021

Drug Res (Stuttg)

View full text Add to dashboard Cite

The inflammatory disease’s increased prevalence leads to a major concern around the world. Still, there is a lack of effective and successful therapy in the reversal of Inflammatory Bowel Disease (IBD) symptoms. Whereas, reactive oxygen species (ROS) production and muddled defense capacity of antioxidants in IBD subjects reported several times. Many proton pump inhibitors have been reported previously for their anti-inflammatory effect. The present study is aimed to assess the ameliorative effect of lansoprazole in experimentally induced IBD in rats. Thirty-six female Sprague Dawley rats were divided equally into six groups based on their body weight. Lansoprazole (1, 5, and 10 mg/kg, p.o.) and 5-aminosalicylate (5-ASA, 100 mg/kg, p.o.) served as standard control respectively, given for 18 days once a day. On the 11th day of the study, colitis was induced by intrarectal instillation of 2, 4-Dinitrobenzene sulfonic acid (DNBS), and treatment was continued for the next 7 days. Administration of lansoprazole (at 5 and 10 mg/kg) significantly reduced DAI (Disease Activation Index) and CMDI (Colon Macroscopic Damage Index); which further justifies a reduction in colon inflammation grades, as well as histopathological changes, and reflected by the stalling of body weight. The anti-inflammatory effects were indicated by lowered MPO (myeloperoxidase) and SOD (superoxide dismutase) in colon tissue as well as restores colonic NO (nitric oxide) level. The study shows lansoprazole improved DAI and CMDI scores, reduction of neutrophil infiltration, and an improved antioxidant status indicating an anti-ulcerative effect in DNBS-induced experimental colitis that is comparable with 5-ASA treatment.

show abstract

Lansoprazole for maintenance therapy of peptic ulcer: Weekend full-dose or everyday half-dose?

Cited by 2 publications

References 0 publications

Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse

Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse

Lansoprazole a Proton Pump Inhibitor Prevents IBD by Reduction of Oxidative Stress and NO Levels in the Rat

Contact Info

Product

Resources

About